Moderna AI mRNA therapy wins Phase 3 as analysts challenge cure-timeline claims

Merck and Moderna reported a positive Phase 3 result for an individualized AI-designed mRNA cancer therapy: the AI analyzes sequencing data from a patient's tumor and blood, predicts up to 34 neoantigens most likely to trigger an immune response, and the resulting custom therapy is paired with KEYTRUDA. In a melanoma trial, this combination significantly improved recurrence-free and distant-metastasis-free survival compared with KEYTRUDA alone; overall-survival follow-up data remains ongoing. A detailed analysis published the same day argues that despite over $70 billion invested in AI for life sciences between 2020 and 2024, no AI-discovered drug has reached market, and fundamental bottlenecks, including scarce real-world data, the pace of biological processes, and clinical trial constraints, prevent AI from delivering on broader cancer cure timelines.